Please login to the form below

Not currently logged in
Email:
Password:

Nabriva Therapeutics appoints chief medical officer

Jennifer Schranz will lead the company’s clinical development business

Jennifer SchranzNabriva Therapeutics, a biopharma focused on treating bacterial infections, has appointed a new chief medical officer in the form of Jennifer Schranz.

Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs.

Commenting on the appointment, Dr Colin Broom, chief executive officer of Nabriva, said: “Jennifer has broad expertise in infectious diseases and internal medicine with extensive experience in both clinical development and medical affairs for small molecules and biologics.

“She brings a track record of successful navigating the regulatory submission and approval process, as well as leading medical affairs activities and will be an invaluable member of our team as we continue to advance the legamulin programme toward a potential approval for the treatment of community-acquired bacterial pneumonia.”

Dr Schran’z new role will see her lead clinical development and medical affairs, contributing to the company’s business development strategy.

Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck & Co.

3rd April 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics